Global Cancer Cachexia Market

1. Summary

The Global Cancer Cachexia Market was valued at $2.8 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 4.7% CAGR, to an estimated market size of $3.5 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The global cancer cachexia market comprises pharmacological interventions, nutritional support, and multimodal management programs designed to treat a complex metabolic syndrome characterized by involuntary weight loss, muscle atrophy, and fatigue in cancer patients. The scope includes appetite stimulants, corticosteroids, progestogens, and emerging anabolic agents aimed at improving patient quality of life and maintaining chemotherapy dose intensity.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the Cancer Cachexia Market in the period 2025-30:

• The market is shifting from viewing cachexia as a palliative endpoint to a distinct, treatable chronic comorbidity.
• Rising global cancer prevalence and increased survival rates are extending the clinical window for metabolic interventions.
• There is a significant trend toward multimodal treatment adoption, combining pharmaceutical therapy with dietary counseling and exercise.
• Pipeline innovation is increasingly focused on precision interventions targeting GDF-15, myostatin, and dual anabolic-catabolic pathways.
• Regulatory bodies are providing expedited approval pathways and incentives for orphan drug development to address high unmet clinical needs.
• The discovery of specific biomarkers is enabling more accurate diagnosis and personalized management of pre-cachexia stages.
• Market growth is supported by the commercial success of novel agents like Anamorelin in key markets such as Japan.

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments: